Prostate cancer is the second most common cancer in men worldwide, with nearly 1.4 million new cases diagnosed each year. PARP inhibitors have transformed the treatment landscape for ...
Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
In mammals, 17 PARP family members have been discovered, and only 6 of these synthesize poly ADP-ribose (pADPr). PARP1, PARP2, and PARP3 have roles in DNA repair. PARP1 binds to DNA that has suffered ...
Please provide your email address to receive an email when new articles are posted on . Treatment with the PARP inhibitor olaparib induced a high response rate among patients with metastatic prostate ...
Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant DNA end-sensing and binding molecule. Inactivation of PARP-1 by chemicals and genetic mutations slows cell proliferation, increases sister ...
Although the first foray into the clinic for PARP inhibitors was in combination with DNA-damaging chemotherapy, clinical development was limited by the more-than-additive toxicity, in particular ...
Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach. In ...
Racial disparities in radium-223 treatment in a large real-world population. Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive ...
Studies by a Dana-Farber Cancer Institute (DFCI)-led research team suggest that disabling immune suppression mediated by a specific type of macrophage may boost the effectiveness of poly ADP ribose ...
An educational session helps oncologists understand the decision-making process for selecting treatments for recurrent ovarian cancer. New therapeutic options—with more on the horizon—offer ...
Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results